Abstract
Hypertension is often accompanied by a variety of metabolic abnormalities. These metabolic abnormalities include insulin resistance, dyslipidemia and abnormalities of the coagulation-fibrinolytic system predisposing to a procoagulent state. The nexus for all of these abnormalities may be central (visceral) obesity. The dyslipidemia accompanying hypertension consists of low HDL cholesterol, elevated triglyceride levels and an abnormal more atherogenic LDL cholesterol particle. Dyslipidemia interacts with associated hemodynamic (ie, hypertension) and metabolic (ie, increased platelet aggregation and PAI-1 levels) in a multiplicative manner potentiating cardiovascular and renal disease. Accordingly, lipid therapy should be aggressive to attenuate these medical complications of essential hypertension.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Sowers, J. Impact of lipid and ACE inhibitor therapy on cardiovascular disease and metabolic abnormalities in the diabetic and hypertensive patient. J Hum Hypertens 11, 9–16 (1997). https://doi.org/10.1038/sj.jhh.1000394
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/sj.jhh.1000394
- Springer Nature Limited
Keywords
This article is cited by
-
A multi-ethnic polygenic risk score is associated with hypertension prevalence and progression throughout adulthood
Nature Communications (2022)
-
Genome scan for quantitative trait loci influencing HDL levels: evidence for multilocus inheritance in familial combined hyperlipidemia
Human Genetics (2005)
-
Higher blood pressure in middle-aged American adults with less education—role of multiple dietary factors: The INTERMAP Study
Journal of Human Hypertension (2003)